Suzanne G Paradis

US Patent:

7414169, Aug 19, 2008

Filed:

Apr 27, 2001

Appl. No.:

09/844353

Inventors:

Gary Ruvkun - Newton MA, US
Koutarou Kimura - Boston MA, US
Garth Patterson - Charlestown MA, US
Scott Ogg - Newton MA, US
Suzanne Paradis - Somerville MA, US
Heidi Tissenbaum - Belmont MA, US
Jason Morris - New York NY, US
Allison Koweek - Somerville MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

G01N 33/00
A01K 67/00
A01N 37/18
C12P 21/06
C12N 15/63
C12N 5/00

US Classification:

800 3, 800 8, 800 9, 435 691, 4353201, 435325, 435455, 514 2

Abstract:

Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.

US Patent:

62251201, May 1, 2001

Filed:

May 15, 1997

Appl. No.:

8/857076

Inventors:

Gary Ruvkun - Newton MA
Koutarou Kimura - Boston MA
Garth Patterson - Charlestown MA
Scott Ogg - Newton MA
Suzanne Paradis - Somerville MA
Heidi Tissenbaum - Belmont MA
Jason Morris - New York NY
Allison Koweek - Somerville MA

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

C12N 500
C12N 1500
A01K 6700

US Classification:

435375

Abstract:

Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.

US Patent:

20160177314, Jun 23, 2016

Filed:

Jan 29, 2014

Appl. No.:

14/892629

Inventors:

- Waltham MA, US
Mei ZENG - Newton MA, US
Suzanne PARADIS - Lexington MA, US
Marissa KUZIRIAN - Waltham MA, US

International Classification:

C12N 15/113

Abstract:

Disclosed are improved shRNA molecules, termed “organic shRNA” (OshRNA), that incorporate certain structural features that increase the likelihood that the desired guide strand is produced while reducing accumulation of passenger strands that might contribute to off-target effects. Also provided herein are nucleic acids encoding OshRNAs, kits, cells, and transgenic animals comprising such nucleic acids, as well as methods of making and using OshRNAs and/or nucleic acids encoding OshRNAs.

US Patent:

20150361156, Dec 17, 2015

Filed:

Jan 24, 2014

Appl. No.:

14/761983

Inventors:

Suzanne PARADIS - Lexington MA, US
Anna R. MOORE - Newton MA, US
Marissa S. KUZIRIAN - Waltham MA, US

International Classification:

C07K 14/705
C12N 15/113
A61K 38/17

Abstract:

The present technology relates to methods of modulating the number of GABAergic synapses between at least two neurons. These methods include contacting at least one of the neurons with a PlexinB agonist or a nucleic acid molecule encoding a PlexinB agonist, such as a composition including a Sema4D polypeptide or an extracellular fragment thereof, or a nucleic acid molecule encoding the Sema4D polypeptide or extracellular fragment thereof. The present technology also relates to methods of modulating neuronal activity in the central nervous system or peripheral nervous system of a subject in need thereof by modulating the number of GABAergic synapses between at least two neurons. The present technology further relates to methods of treating a neuro logical disorder that would benefit from modulating neuronal activity in the central nervous system or peripheral nervous system of a subject in need thereof.